Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 31 Records) |
| Query Trace: Breast Neoplasms and CYP2C9[original query] |
|---|
| Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clinica chimica acta; international journal of clinical chemistry 2006 Nov 373 (1-2): 99-103. Zhang Wei, Yu Bang-Ning, He Yi-Jing, Fan Lan, Li Qing, Liu Zhao-Qian, Wang An, Liu Ya-Li, Tan Zhi-Rong, Fen-Jiang , Huang Yuan-Fei, Zhou Hong-H |
| Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Nov 25 (33): 5187-93. Schroth Werner, Antoniadou Lydia, Fritz Peter, Schwab Matthias, Muerdter Thomas, Zanger Ulrich M, Simon Wolfgang, Eichelbaum Michel, Brauch Hiltr |
| Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. Journal of human genetics 2009 Oct 54 (10): 564-71. Low Siew-Kee, Kiyotani Kazuma, Mushiroda Taisei, Daigo Yataro, Nakamura Yusuke, Zembutsu Hitos |
| Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast cancer research and treatment 2010 Jan 119 (2): 463-74. Authors are not available |
| Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. International journal of cancer. Journal international du cancer 2009 Aug 125 (4): 837-43. Sangrajrang Suleeporn, Sato Yasunori, Sakamoto Hiromi, Ohnami Sumiko, Laird Nan M, Khuhaprema Thiravud, Brennan Paul, Boffetta Paolo, Yoshida Teruhi |
| CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. British journal of cancer 2009 Dec 101 (11): 1817-23. Jernström H, Bågeman E, Rose C, Jönsson P-E, Ingvar |
| Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast cancer research : BCR 2010 12 (3): R26. Gor Priya P, Su H Irene, Gray Robert J, Gimotty Phyllis A, Horn Michelle, Aplenc Richard, Vaughan William P, Tallman Martin S, Rebbeck Timothy R, DeMichele Ange |
| Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circulation. Cardiovascular genetics 2010 Jun 3 (3): 276-85. Bailey Kristian M, Romaine Simon P R, Jackson Beryl M, Farrin Amanda J, Efthymiou Maria, Barth Julian H, Copeland Joanne, McCormack Terry, Whitehead Andrew, Flather Marcus D, Samani Nilesh J, Nixon Jane, Hall Alistair S, Balmforth Anthony J, |
| Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British journal of cancer 2010 Mar 102 (6): 1003-9. Bray J, Sludden J, Griffin M J, Cole M, Verrill M, Jamieson D, Boddy A |
| Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic & clinical pharmacology & toxicology 2010 Jul 107 (1): 570-6. Afsar Nasir Ali, Haenisch Sierk, Mateen Ahmed, Usman Ahmed, Ufer Mike, Ahmed Khwaja Zafar, Ahmad Hakimuddin Razi, Cascorbi Ingo |
| Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. British journal of clinical pharmacology 2011 May 71 (5): 737-50. Lim Joanne S L, Chen Xiang A, Singh Onkar, Yap Yoon S, Ng Raymond C H, Wong Nan S, Wong Mabel, Lee Edmund J D, Chowbay Balr |
| Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clinical pharmacology and therapeutics 2011 May 89 (5): 708-17. Mürdter T E, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching P A, Fehm T, , Eichelbaum M, Schwab M, Brauch |
| Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. Cancer chemotherapy and pharmacology 2011 Oct 68 (4): 897-904. Fernandes Bruno José Dumêt, Silva Carolina de Miranda, Andrade Jurandyr Moreira, Matthes Angelo do Carmo Silva, Coelho Eduardo Barbosa, Lanchote Vera Luc |
| Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. European journal of clinical pharmacology 2012 Apr 68 (4): 389-95. Afsar Nasir Ali, Ufer Mike, Haenisch Sierk, Remmler Cornelia, Mateen Ahmed, Usman Ahmed, Ahmed Khwaja Zafar, Ahmad Hakimuddin Razi, Cascorbi Ingo |
| Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC medical genetics 2012 13 (1): 45. Seredina Tatyana A, Goreva Olga B, Talaban Valeria O, Grishanova Alevtina Yu, Lyakhovich Vyacheslav |
| Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast cancer research and treatment 2014 Oct 147 (3): 557-70. Vulsteke C, Pfeil A M, Schwenkglenks M, Pettengell R, Szucs T D, Lambrechts D, Peeters M, van Dam P, Dieudonné A S, Hatse S, Neven P, Paridaens R, Wildiers |
| Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. Clinica chimica acta; international journal of clinical chemistry 2014 Jul 434 21-8. Tulsyan Sonam, Agarwal Gaurav, Lal Punita, Mittal Balr |
| Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer chemotherapy and pharmacology 2014 Jun 73 (6): 1181-8. Mwinyi Jessica, Vokinger Kerstin, Jetter Alexander, Breitenstein Urs, Hiller Christian, Kullak-Ublick Gerd A, Trojan Andre |
| Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. Breast cancer research and treatment 2014 Dec 148 (3): 571-80. Rangel Leticia B A, Taraba Jodi L, Frei Christopher R, Smith Lon, Rodriguez Gladys, Kuhn John |
| CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss. Journal of molecular endocrinology 2015 Aug 55 (1): 69-79. Rodríguez-Sanz M, García-Giralt N, Prieto-Alhambra D, Servitja S, Balcells S, Pecorelli R, Díez-Pérez A, Grinberg D, Tusquets I, Nogués |
| Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. Journal of clinical pharmacology 2016 May . Powers Jennifer L, Buys Saundra S, Fletcher Deborah, Melis Roberta, Johnson-Davis Kamisha, Lyon Elaine, Malmberg Elisabeth M, McMillin Gwendolyn |
| Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenetics and genomics 2017 9 27 (11): 402-409. Marcath Lauren A, Deal Allison M, Van Wieren Emily, Danko William, Walko Christine M, Ibrahim Joseph G, Weck Karen E, Jones David R, Desta Zeruesenay, McLeod Howard L, Carey Lisa A, Irvin William J, Hertz Daniel |
| Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population. BMC medical genetics 2019 Sep 20 (1): 148. Al-Eitan Laith N, Rababa'h Doaa M, Alghamdi Mansour A, Khasawneh Rame |
| CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients. Cancers 2019 9 11 (9): . Ahmed Jemal Hussien, Makonnen Eyasu, Fotoohi Alan, Aseffa Abraham, Howe Rawleigh, Aklillu Ele |
| CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients. Frontiers in pharmacology 2019 5 10 481. Ahmed Jemal Hussien, Makonnen Eyasu, Yimer Getnet, Seifu Daniel, Bekele Abebe, Assefa Mathewos, Aseffa Abraham, Howe Rawleigh, Fotoohi Alan, Hassan Moustapha, Aklillu Ele |
| Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. Frontiers in pharmacology 2020 5 11 406. Ahmed Jemal Hussien, Makonnen Eyasu, Bisaso Ronald Kuteesa, Mukonzo Jackson Kijumba, Fotoohi Alan, Aseffa Abraham, Howe Rawleigh, Hassan Moustapha, Aklillu Ele |
| Biochip-based approach for comprehensive pharmacogenetic testing. Drug metabolism and personalized therapy 2020 Dec . Ikonnikova Anna Yu, Filippova Marina A, Surzhikov Sergey A, Pozhitnova Victoria O, Kazakov Ruslan E, Lisitsa Tatiana S, Belkov Sergey A, Nasedkina Tatiana |
| Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions. Pharmacogenomics and personalized medicine 2021 14 279-286. Jeiziner Chiara, Stäuble Céline K, Lampert Markus L, Hersberger Kurt E, Meyer Zu Schwabedissen Henriette |
| Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes. European journal of clinical pharmacology 2021 1 77 (8): 1095-1111. Wang Tingyu, Zhou Yitian, Cao Guoshe |
| Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing. Drug metabolism and personalized therapy 2023 7 . Ekaterina Olegovna Golubenko, Marina Ivanovna Savelyeva, Zhannet Alimovna Sozaeva, Vera Vyacheslavovna Korennaya, Irina Vladimirovna Poddubnaya, Timur Tejmurazovich Valiev, Svetlana Nikolaevna Kondratenko, Mikhail Vitalyevich Ily |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 18, 2023
- Content source: